HK1213918A1 - 治療杜興氏肌營養不良的抗 抗體 - Google Patents

治療杜興氏肌營養不良的抗 抗體

Info

Publication number
HK1213918A1
HK1213918A1 HK16101850.9A HK16101850A HK1213918A1 HK 1213918 A1 HK1213918 A1 HK 1213918A1 HK 16101850 A HK16101850 A HK 16101850A HK 1213918 A1 HK1213918 A1 HK 1213918A1
Authority
HK
Hong Kong
Prior art keywords
flt
antibodies
muscular dystrophy
duchenne muscular
treating duchenne
Prior art date
Application number
HK16101850.9A
Other languages
English (en)
Inventor
‧約西亞
‧盧比
‧朝倉
‧基夫
‧查納斯
Original Assignee
Shire Human Genetic Therapies
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies, Univ Minnesota filed Critical Shire Human Genetic Therapies
Publication of HK1213918A1 publication Critical patent/HK1213918A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK16101850.9A 2013-01-28 2016-02-18 治療杜興氏肌營養不良的抗 抗體 HK1213918A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361757571P 2013-01-28 2013-01-28
PCT/US2014/013402 WO2014117160A1 (en) 2013-01-28 2014-01-28 Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
HK1213918A1 true HK1213918A1 (zh) 2016-07-15

Family

ID=50073518

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16101850.9A HK1213918A1 (zh) 2013-01-28 2016-02-18 治療杜興氏肌營養不良的抗 抗體
HK16105498.8A HK1217710A1 (zh) 2013-01-28 2016-05-13 治療杜興氏肌營養不良的抗 抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16105498.8A HK1217710A1 (zh) 2013-01-28 2016-05-13 治療杜興氏肌營養不良的抗 抗體

Country Status (14)

Country Link
US (3) US9957324B2 (zh)
EP (1) EP2948476B1 (zh)
JP (2) JP6469022B2 (zh)
KR (1) KR102259255B1 (zh)
CN (1) CN104955843B (zh)
AU (1) AU2014209012B2 (zh)
BR (1) BR112015017242B1 (zh)
CA (1) CA2898998C (zh)
EA (1) EA037501B1 (zh)
ES (1) ES2676406T3 (zh)
HK (2) HK1213918A1 (zh)
IL (1) IL238588B (zh)
MX (1) MX360153B (zh)
WO (1) WO2014117160A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948164B1 (en) 2013-01-28 2019-04-10 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
JP6797825B2 (ja) * 2015-04-07 2020-12-09 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 気管支肺異形成症を治療する抗ｆｌｔ−１抗体
BR112017021413A2 (pt) * 2015-04-07 2018-07-03 Shire Human Genetic Therapies anticorpos anti-flt-1 no tratamento da displasia broncopulmonar.
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
KR20230140362A (ko) 2022-03-24 2023-10-06 주식회사 케이에스비튜젠 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2590671A1 (en) * 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1

Also Published As

Publication number Publication date
EA201590720A8 (ru) 2018-09-28
EP2948476A1 (en) 2015-12-02
US9957324B2 (en) 2018-05-01
US20150361174A1 (en) 2015-12-17
US20210163603A1 (en) 2021-06-03
JP2016511234A (ja) 2016-04-14
BR112015017242B1 (pt) 2023-11-07
KR102259255B1 (ko) 2021-05-31
IL238588B (en) 2020-04-30
WO2014117160A1 (en) 2014-07-31
ES2676406T3 (es) 2018-07-19
IL238588A0 (en) 2015-06-30
EA201590720A1 (ru) 2015-11-30
US20180312593A1 (en) 2018-11-01
CN104955843A (zh) 2015-09-30
JP2019023230A (ja) 2019-02-14
KR20150109386A (ko) 2015-10-01
EA037501B1 (ru) 2021-04-05
CN104955843B (zh) 2019-08-13
EP2948476B1 (en) 2018-06-06
BR112015017242A2 (zh) 2017-08-15
JP6469022B2 (ja) 2019-02-13
CA2898998A1 (en) 2014-07-31
MX360153B (es) 2018-10-24
AU2014209012B2 (en) 2018-11-08
MX2015009690A (es) 2016-03-31
CA2898998C (en) 2023-02-14
HK1217710A1 (zh) 2017-01-20
AU2014209012A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
HK1217637A1 (zh) 治療杜興氏肌營養不良的卵泡抑素
HK1217710A1 (zh) 治療杜興氏肌營養不良的抗 抗體
HK1208470A1 (zh) 用於整合蛋白療法應用的生物標記
ZA201408955B (en) Anti-blys antibody
EP2968273A4 (en) METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES
HK1205523A1 (zh) 抗-大-內皮素- 抗體及其用途
GB201304046D0 (en) Localised energy concentration
GB2523058B (en) Measuring settling in fluid mixtures
GB201420587D0 (en) Polymer process
PL2965322T3 (pl) Miejscowa koncentracja energii
EP2975068A4 (en) METHOD FOR PRODUCING AN ALPHA OLEFIN POLYMER AND A HYDROGENATED ALPHA OLEFINE POLYMER
GB2509517B (en) Computing apparatus
HK1220736A1 (zh) 尿液中的 檢測
IL236714A0 (en) Anti-her2 antibodies with reduced fucosylation for use in cancer therapy
EP2972714A4 (en) PROVIDING A HYBRID TOUCH PAD ON A COMPUTER DEVICE
HK1249912A1 (zh) 用於治療杜氏肌營養不良的抗flt-1抗體
GB2508477B (en) Computing apparatus and method
GB201305687D0 (en) Radiolabelling process
EP2986341A4 (en) ANGIOTENSINS IN MUSCULAR DYSTROPHY
GB2519413B (en) Catalyst and process
GB201413378D0 (en) Improvements in shopping trolleys
GB201313937D0 (en) Polymerisation process
EP2831915A4 (en) DNA COMPUTING
IL245222B (en) A method for discovering DNA
GB201319273D0 (en) Improvements in structural members and methods relating thereto

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: ADDITION OF INVENTOR: MAYANK VERMA - M

Effective date: 20181221